These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. CBX7 suppresses cell proliferation, migration, and invasion through the inhibition of PTEN/Akt signaling in pancreatic cancer. Ni S; Wang H; Zhu X; Wan C; Xu J; Lu C; Xiao L; He J; Jiang C; Wang W; He Z Oncotarget; 2017 Jan; 8(5):8010-8021. PubMed ID: 28030829 [TBL] [Abstract][Full Text] [Related]
26. GNAS(R201H) and Kras(G12D) cooperate to promote murine pancreatic tumorigenesis recapitulating human intraductal papillary mucinous neoplasm. Taki K; Ohmuraya M; Tanji E; Komatsu H; Hashimoto D; Semba K; Araki K; Kawaguchi Y; Baba H; Furukawa T Oncogene; 2016 May; 35(18):2407-12. PubMed ID: 26257060 [TBL] [Abstract][Full Text] [Related]
27. The biological features of PanIN initiated from oncogenic Kras mutation in genetically engineered mouse models. Shen R; Wang Q; Cheng S; Liu T; Jiang H; Zhu J; Wu Y; Wang L Cancer Lett; 2013 Oct; 339(1):135-43. PubMed ID: 23887057 [TBL] [Abstract][Full Text] [Related]
28. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16. Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115 [TBL] [Abstract][Full Text] [Related]
29. Lunatic Fringe is a potent tumor suppressor in Kras-initiated pancreatic cancer. Zhang S; Chung WC; Xu K Oncogene; 2016 May; 35(19):2485-95. PubMed ID: 26279302 [TBL] [Abstract][Full Text] [Related]
30. The regulatory roles of miRNA and methylation on oncogene and tumor suppressor gene expression in pancreatic cancer cells. Wang X; Zhao J; Huang J; Tang H; Yu S; Chen Y Biochem Biophys Res Commun; 2012 Aug; 425(1):51-7. PubMed ID: 22820191 [TBL] [Abstract][Full Text] [Related]
31. Epicatechin-rich cocoa polyphenol inhibits Kras-activated pancreatic ductal carcinoma cell growth in vitro and in a mouse model. Siddique HR; Liao DJ; Mishra SK; Schuster T; Wang L; Matter B; Campbell PM; Villalta P; Nanda S; Deng Y; Saleem M Int J Cancer; 2012 Oct; 131(7):1720-31. PubMed ID: 22190076 [TBL] [Abstract][Full Text] [Related]
32. Hilar cholangiocarcinoma and pancreatic ductal adenocarcinoma share similar histopathologies, immunophenotypes, and development-related molecules. Gandou C; Harada K; Sato Y; Igarashi S; Sasaki M; Ikeda H; Nakanuma Y Hum Pathol; 2013 May; 44(5):811-21. PubMed ID: 23134772 [TBL] [Abstract][Full Text] [Related]
33. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice. Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677 [TBL] [Abstract][Full Text] [Related]
34. Levels of the Autophagy-Related 5 Protein Affect Progression and Metastasis of Pancreatic Tumors in Mice. Görgülü K; Diakopoulos KN; Ai J; Schoeps B; Kabacaoglu D; Karpathaki AF; Ciecielski KJ; Kaya-Aksoy E; Ruess DA; Berninger A; Kowalska M; Stevanovic M; Wörmann SM; Wartmann T; Zhao Y; Halangk W; Voronina S; Tepikin A; Schlitter AM; Steiger K; Artati A; Adamski J; Aichler M; Walch A; Jastroch M; Hartleben G; Mantzoros CS; Weichert W; Schmid RM; Herzig S; Krüger A; Sainz B; Lesina M; Algül H Gastroenterology; 2019 Jan; 156(1):203-217.e20. PubMed ID: 30296435 [TBL] [Abstract][Full Text] [Related]
35. Liver-specific knockout of GRP94 in mice disrupts cell adhesion, activates liver progenitor cells, and accelerates liver tumorigenesis. Chen WT; Tseng CC; Pfaffenbach K; Kanel G; Luo B; Stiles BL; Lee AS Hepatology; 2014 Mar; 59(3):947-57. PubMed ID: 24027047 [TBL] [Abstract][Full Text] [Related]
36. Ductal origin of pancreatic adenocarcinomas induced by conditional activation of a human Ha-ras oncogene in rat pancreas. Ueda S; Fukamachi K; Matsuoka Y; Takasuka N; Takeshita F; Naito A; Iigo M; Alexander DB; Moore MA; Saito I; Ochiya T; Tsuda H Carcinogenesis; 2006 Dec; 27(12):2497-510. PubMed ID: 16774944 [TBL] [Abstract][Full Text] [Related]
37. Critical role of oncogenic KRAS in pancreatic cancer (Review). Liu J; Ji S; Liang C; Qin Y; Jin K; Liang D; Xu W; Shi S; Zhang B; Liu L; Liu C; Xu J; Ni Q; Yu X Mol Med Rep; 2016 Jun; 13(6):4943-9. PubMed ID: 27121414 [TBL] [Abstract][Full Text] [Related]
38. KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach. Yoon YK; Kim HP; Han SW; Oh DY; Im SA; Bang YJ; Kim TY Mol Carcinog; 2010 Apr; 49(4):353-62. PubMed ID: 20358631 [TBL] [Abstract][Full Text] [Related]
39. Mutant KRAS in the initiation of pancreatic cancer. Deramaudt T; Rustgi AK Biochim Biophys Acta; 2005 Nov; 1756(2):97-101. PubMed ID: 16169155 [TBL] [Abstract][Full Text] [Related]
40. Activation Of Wild-Type Hras Suppresses The Earliest Stages Of Pancreatic Cancer. Weyandt J Redox Biol; 2015 Aug; 5():414. PubMed ID: 28162272 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]